Cargando…
The economic pressures for biosimilar drug use in cancer medicine
The main rationale for using biosimilar drugs is for cost saving. The market development for biosimilar drugs will therefore depend on the degree to which cost saving measures are required by nations, medical insurers and individuals and the absolute savings that could be gained by switching from or...
Autor principal: | Cornes, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291824/ https://www.ncbi.nlm.nih.gov/pubmed/22249658 http://dx.doi.org/10.1007/s11523-011-0196-3 |
Ejemplares similares
-
Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019) -
Advancing Biosimilar Development Using Pharmacodynamic Biomarkers in Clinical Pharmacology Studies
por: Li, Junyi, et al.
Publicado: (2019) -
Biosimilars: new promise for reducing healthcare costs
por: Munsch, Julia
Publicado: (2014) -
Biosimilars Adoption: Recognizing and Removing the RoadBlocks
por: Niazi, Sarfaraz K
Publicado: (2023) -
Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars
por: Niazi, Sarfaraz
Publicado: (2022)